The question of FK 506 nephrotoxicity after liver transplantation

Abstract

Formal studies have not been published on the nephrotoxicity of FK 506 when the drug was used from the outset. This kind of information was sought in 101 recipients of primary livers, 24 hearts, and 3 double lungs or heart-lung. Perioperative renal dysfunction was commonly seen, which appeared to be related to FK 506 doses and plasma levels, particularly when the drug was given IV. This was reversible. Late renal function has been generally satisfactory in all three cohorts of patients, and the incidence of hypertension has been low. The therapeutic index of FK 506 is a good one, as revealed by these observations in patients whose most notable achievement was a low mortality.

Fig 1

Scr in heart transplants. Mean ± standard error for heart transplant patients. Values from day 0 to 30 are expressed as mean ± standard error at 5-day intervals.

Fig 2

Scr in heart transplants. Individual clinical courses of a heart-lung and two double lung recipients who were treated with FK 506 only.

Fig 3

Serum creatinine in 101 primary liver transplant recipients. Values from day 0 to 30 are expressed as mean ± standard error at 5-day intervals.